The Mitogen Activated Protein Kinase (MAPK) pathway plays a key role in melanoma
development making it an important therapeutic target. In normal cells, the tightly regulated …

Melanoma derived from melanocytes is the most aggressive genre of skin cancer. Although
the considerable advancement in the study of human cancer biology and drug discovery …

Purpose: To compare the efficacy and tolerability of the mitogen-activated protein
(MAP)/extracellular signal-regulated (ERK) kinase (MEK) 1/2 inhibitor selumetinib versus …

Cancer progression and outcome depend upon two key functions executed by tumor cells:
the growth and survival capability leading to resistance to therapy and the invasion into host …

Cancer is one of the major causes of mortality and morbidity worldwide. Substantial
research efforts have been made to develop new chemical entities with improved anticancer …

BRAF is a serine-threonine–specific protein kinase that is mutated in 2% of human cancers.
Oncogenic BRAF is a validated therapeutic target that constitutively activates mitogen …

Malignant melanoma is an aggressive tumor of the skin with a poor prognosis for patients
with advanced disease. It is resistant to current therapeutic approaches. In melanoma, both …

Melanoma is a progressive disease that claims many lives each year due to lack of
therapeutics effective for the long‐term treatment of patients. Currently, the best treatment …

Purpose: Deregulation of phosphatidylinositol 3-kinase/Akt and Ras/Raf/mitogen-activated
protein kinase/extracellular signal-regulated kinase kinase/extracellular signal-regulated …

Melanoma is the least common form of skin cancer, but it is responsible for the majority of
skin cancer deaths. Traditional therapeutics and immunomodulatory agents have not shown …